Targets › SOS1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2027.
Promotes the exchange of Ras-bound GDP by GTP. Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3/ERK1 in response to EGF. Catalytic component of a trimeric complex that participates in transduction of signals from Ras to Rac by promoting the Rac-specific guanine nucleotide exchange factor (GEF) activity (By similarity). (UniProt, Q07889)
Open in Phaseline: the race on SOS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bayer | BAY3498264 SOS1 inhibitor | SOS1 | Phase 1 | Advanced Solid Tumors Harboring KRAS G12C Mutation | Apr 2027 |
Advanced Solid Tumors Harboring KRAS G12C Mutation (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.